Scleroderma Queensland
  • Home
  • About Us
    • Your Committee
    • Members' Stories
  • Become a Member
    • Printable Membership Form
    • Online Membership Form
  • Donations
  • RESEARCH
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • GET SUPPORT
  • RESOURCES
  • Contact Us
  • Newsletter
  • MERCHANDISE

Cerebrovascular, cardiovascular disease risk seen higher in SSc

9/5/2024

 
Meta-analysis has implications for prognosis and prevention, researchers sayby Andrea Lobo, PhD | April 23, 2024
Picture
​Having scleroderma increases the risk of developing diseases affecting blood vessels of the brain or heart, known as cerebrovascular and cardiovascular diseases, a review study found.

Relative to controls, the risk of stroke — caused by poor blood flow to the brain — in scleroderma patients was 64% higher, whereas that of cardiovascular disease was 112% higher.
“Our findings support increased clinical surveillance and consideration of preventative strategies in this high-risk population,” researchers in Taiwan wrote.

Their study, “Association between systemic sclerosis and risk of cerebrovascular and cardiovascular disease: a meta-analysis,” was published in Scientific Reports.

Scleroderma, also known as systemic sclerosis (SSc), is characterized by the excessive production of collagen that leads to the accumulation of scar tissue, affecting the skin and potentially internal organs, such as the digestive tract and lungs. The disease may also damage blood vessels, both small and large, leading to complications such as pulmonary arterial hypertension and scleroderma renal crisis.
​
Evidence has suggested that people with scleroderma may have an increased risk of stroke, heart attack, and peripheral vascular disease, which is reduced circulation in blood vessels outside the brain and heart. However, “the risk of cerebrovascular and cardiovascular complications attributed to SSc remains debated,” the researchers wrote.
​The study and its findings
To explore this topic further, the scientists conducted a systematic review of published research and a meta-analysis, which pools data from multiple studies. More details can be found in PROSPERO (CRD42023471039), an international prospective register of systematic reviews.

The analysis included 17 studies with 6,642,297 participants from different geographical regions (U.S., Europe, and Taiwan). The mean age of the participants ranged from 35 to 60.9 years; they were mostly female and were followed up for periods between one and 14 years.

Overall, 11 studies with 1,157,175 participants reported an association between scleroderma and stroke; compared to controls, SSc patients were at a 64% higher risk of having a stroke. Subgroup analysis revealed that the risk was increased by 55% in non-Asians; in Asians (from Taiwan) the risk also was higher, but the difference was not statistically different.

Seven studies involving 5,524,044 participants identified a more than two times greater risk for cardiovascular disease in scleroderma patients.

People with SSc were also over two times more likely to have a heart attack and venous thromboembolism, when a blood clot forms in a vein. Their risk of peripheral vascular disease was more than five times higher.

Regarding other heart disease manifestations, heart failure and atrial fibrillation — an irregular and often very fast heart rhythm — were more common in scleroderma patients, as was the need to have a pacemaker.

A sensitivity analysis showed that the findings were consistent, as the omission of any study from the analysis did not affect the overall results, the scientists stated.

Overall, they said this meta-analysis demonstrates that SSc is associated with an increased cerebrovascular and cardiovascular risk across a broad range of complications, emphasizing bodywide blood vessel disease as a feature of underlying scleroderma processes.
​
According to the researchers, “elucidating the relationship between SSc and cerebrovascular/[cardiovascular diseases] has significant implications for prognosis, screening, prevention, and management.”
Therefore, “future studies should delve deeper into the mechanistic underpinnings of these associations, explore potential interventions, and assess the efficacy of preventative strategies tailored for this high-risk population,” they added.

Comments are closed.

    Author

    Scleroderma Queensland Support Group

    Archives

    June 2025
    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    May 2024
    April 2024
    March 2024
    February 2024
    January 2024
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    March 2020

    Categories

    All
    Announcements
    Community
    Members Stories
    Research
    Resources
    Scleroderma
    Support
    Support Group Meetings
    Useful Links

Scleroderma ​Association of Queensland
ABN 91 905 099 795

​About Us | Members' Stories | Group Meetings | Become a Member
Donate now
Phone 0468 801 021  Email [email protected]
Postal Address 54 Avocado Lane, Maleny, QLD, 4552
©Scleroderma Association of Queensland. ​All rights reserved. Website by Grey and Grey. 
  • Home
  • About Us
    • Your Committee
    • Members' Stories
  • Become a Member
    • Printable Membership Form
    • Online Membership Form
  • Donations
  • RESEARCH
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • GET SUPPORT
  • RESOURCES
  • Contact Us
  • Newsletter
  • MERCHANDISE